SPCs outlive patent protections in 91% of cases, new report reveals
24-06-2021
Lawyers warn of Irish Sea split over SPCs
17-12-2020
SPCs: a deep dive into CJEU case law
23-06-2020
Unitary SPC should follow new patent system: EC official
11-06-2020
Fahroni / Shutterstock.com
The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
CJEU, SPCs, Santen, Arnold & Porter, Beatriz San Martin, Neurim, supplementary protection certificates, marketing authorisation, MA
